<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05068388</url>
  </required_header>
  <id_info>
    <org_study_id>ATOS-016R</org_study_id>
    <nct_id>NCT05068388</nct_id>
  </id_info>
  <brief_title>Effect of Oral (Z)-Endoxifen in Premenopausal Women With Measurable Breast Density</brief_title>
  <official_title>A Phase 2, Randomized, Double-blinded, Placebo-controlled, Dose-Response Study of Oral (Z)-Endoxifen in Premenopausal Women With Measurable Breast Density</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Atossa Genetics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Atossa Genetics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blinded, placebo-controlled dose-response efficacy study of oral&#xD;
      (Z)-endoxifen in premenopausal women with measurable breast density. There will be 5&#xD;
      in-clinic visits (Screening, Day 1, Months 1, 3 and 6) and 3 self-report visits (Months 2, 4&#xD;
      and 5). Standard of care mammograms will be used for the screening mammogram as well as the&#xD;
      24-month follow up visit.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 8, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">July 28, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of mammographic density area (cm2) assessed by iCAD® software</measure>
    <time_frame>6 months</time_frame>
    <description>Change from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of mammographic density area (cm2) assessed by iCAD® software</measure>
    <time_frame>3 months</time_frame>
    <description>Change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of mammographic density area (cm2) assessed by Stratus software</measure>
    <time_frame>6 months</time_frame>
    <description>Change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of mammographic density area (cm2) assessed by Stratus software</measure>
    <time_frame>3 months</time_frame>
    <description>Change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline responses to the Breast Cancer Prevention Trial Eight Symptom Scale (BESS)</measure>
    <time_frame>6 months</time_frame>
    <description>5-point Likert-type scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of adverse events</measure>
    <time_frame>6 months</time_frame>
    <description>assessment of adverse events</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Breast Density</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>oral capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1 mg (Z)-endoxifen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 mg (Z)-endoxifen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral capsule</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Z-Endoxifen</intervention_name>
    <description>Z-Endoxifen</description>
    <arm_group_label>1 mg (Z)-endoxifen</arm_group_label>
    <arm_group_label>2 mg (Z)-endoxifen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Premenopausal women (defined as having at least one menstruation during the prior 12&#xD;
             months; women with an intrauterine device are considered premenopausal if &lt;52 years)&#xD;
&#xD;
          2. Women of childbearing potential using a highly effective method of birth control*&#xD;
             throughout the study period and willing to comply with monthly pregnancy testing&#xD;
&#xD;
          3. Screening mammogram performed within 3 month of study inclusion&#xD;
&#xD;
          4. Mammographic density assessed as BI-RADS® score B, C, or D&#xD;
&#xD;
          5. Must have given written informed consent before any study-related activities are&#xD;
             carried out and must be able to understand the full nature and purpose of the trial,&#xD;
             including possible risks and adverse effects&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Mammographic BI-RADS® malignancy code ≥3 at baseline mammography&#xD;
&#xD;
          2. Any previous diagnosis of breast cancer, including carcinoma in situ, or any other&#xD;
             cancer (non-melanoma skin cancer and in situ cancer of the cervix are not exclusion&#xD;
             criteria)&#xD;
&#xD;
          3. A history of breast surgery, e.g., reduction or enlargement, which might affect&#xD;
             mammographic density measurements&#xD;
&#xD;
          4. Current medical conditions:&#xD;
&#xD;
               1. APC (activated protein C) resistance, an inherited coagulation disorder&#xD;
&#xD;
               2. Systolic pressure higher than 160 mm Hg or diastolic higher than 100 mm Hg&#xD;
&#xD;
               3. Cataract(s)&#xD;
&#xD;
               4. Uncontrolled diabetes (defined as HbA1c &gt;50 mmol/mol)&#xD;
&#xD;
               5. Abnormal lab values deemed clinically significant by Investigator&#xD;
&#xD;
          5. BMI &gt; 30&#xD;
&#xD;
          6. Women who have an increased risk of venous thrombosis due to immobilization, e.g.,&#xD;
             using wheelchair&#xD;
&#xD;
          7. Agents that have the potential to decrease endoxifen levels through increased&#xD;
             metabolic clearance:&#xD;
&#xD;
               1. Certain anti-epileptic therapies (carbamazepine, fenytoin, fenobarbital,&#xD;
                  lamotrigine)&#xD;
&#xD;
               2. Certain antibiotics (rifamycins)&#xD;
&#xD;
               3. St John's wort (in Swedish: johannesört)&#xD;
&#xD;
               4. Certain HIV medications (efavirenz, ritonavir)&#xD;
&#xD;
          8. Lactating, pregnant, or plan to become pregnant in the next year&#xD;
&#xD;
          9. History of thromboembolic disease such as embolus, deep vein thrombosis, stroke, TIA&#xD;
             (transient ischemic attack) or myocardial infarction&#xD;
&#xD;
         10. Allergy to endoxifen or any of its components&#xD;
&#xD;
         11. Previous treatment with an anti-oestrogen, including experimental drug studies (e.g.,&#xD;
             Karma CREME, Karisma-1 or Karisma-2)&#xD;
&#xD;
         12. Prescribed and regular use of anticoagulants (defined as substances included in group&#xD;
             B01A in the ATC-system)&#xD;
&#xD;
         13. Participation in another investigational clinical trial in the last 6 months&#xD;
&#xD;
         14. Not willing or able to understand the study information and/or informed consent&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>having at least one menstruation during the prior 12 months; women with an intrauterine device are considered premenopausal if &lt;52 years</gender_description>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Quay, MD</last_name>
    <role>Study Director</role>
    <affiliation>Atossa Therapeutics, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Per Hall, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Södersjukhuset, Stockholm, Sweden</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Heather Fraser, PhD</last_name>
    <phone>206-707-3088</phone>
    <email>heather.fraser@atossainc.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Misty D'Ottavio, RN</last_name>
    <phone>206-348-1804</phone>
    <email>misty.dottavio@atossainc.com</email>
  </overall_contact_backup>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 27, 2021</study_first_submitted>
  <study_first_submitted_qc>September 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2021</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

